Pathology and Pathobiology of Pulmonary Hypertension: Current Insights and Future Directions

Overview

Journal Eur Respir J

Specialty Pulmonary Medicine

Date 2024 Aug 29

PMID 39209474

Authors

Christophe Guignabert

Jurjan Aman

Sebastien Bonnet

Peter Dorfmuller

Andrea J Olschewski

Soni Pullamsetti

Marlene Rabinovitch

Ralph T Schermuly

Marc Humbert

Kurt R Stenmark

Affiliations

Soon will be listed here.

Abstract

In recent years, major advances have been made in the understanding of the cellular and molecular mechanisms driving pulmonary vascular remodelling in various forms of pulmonary hypertension, including pulmonary arterial hypertension, pulmonary hypertension associated with left heart disease, pulmonary hypertension associated with chronic lung disease and hypoxia, and chronic thromboembolic pulmonary hypertension. However, the survival rates for these different forms of pulmonary hypertension remain unsatisfactory, underscoring the crucial need to more effectively translate innovative scientific knowledge into healthcare interventions. In these proceedings of the 7th World Symposium on Pulmonary Hypertension, we delve into recent developments in the field of pathology and pathophysiology, prioritising them while questioning their relevance to different subsets of pulmonary hypertension. In addition, we explore how the latest omics and other technological advances can help us better and more rapidly understand the myriad basic mechanisms contributing to the initiation and progression of pulmonary vascular remodelling. Finally, we discuss strategies aimed at improving patient care, optimising drug development, and providing essential support to advance research in this field.

Citing Articles

Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox.

Pulido T, de la Cruz-Perez S, Valencia D, Conde R, Lescano A, Zayas N Int J Cardiol Congenit Heart Dis. 2025; 19:100573.

PMID: 40066342 PMC: 11891735. DOI: 10.1016/j.ijcchd.2025.100573.

RNA-Seq and ChIP-Seq Identification of Unique and Overlapping Target Genes and Pathways Regulated by TBX4 in Human Pulmonary Fibroblasts and Pericytes.

Cai Y, Yan L, Cogan J, Hedges L, Nunley B, Negretti N Pulm Circ. 2025; 15(1):e70058.

PMID: 39980707 PMC: 11839389. DOI: 10.1002/pul2.70058.

New insights into pulmonary arterial hypertension: interaction between PANoptosis and perivascular inflammatory responses.

Su X, Sun Y, Dai A Apoptosis. 2025; .

PMID: 39979525 DOI: 10.1007/s10495-025-02086-0.

From basic scientific research to the development of new drugs for pulmonary arterial hypertension: insights from activin-targeting agents.

Guignabert C Breathe (Sheff). 2025; 21(1):240116.

PMID: 39845439 PMC: 11747879. DOI: 10.1183/20734735.0116-2024.

Honokiol and Nicotinamide Adenine Dinucleotide Improve Exercise Endurance in Pulmonary Hypertensive Rats Through Increasing SIRT3 Function in Skeletal Muscle.

Li M, McKeon B, Gu S, Prasad R, Zhang H, Kumar S Int J Mol Sci. 2024; 25(21).

PMID: 39519152 PMC: 11545838. DOI: 10.3390/ijms252111600.

References

Travaglini K, Nabhan A, Penland L, Sinha R, Gillich A, Sit R . A molecular cell atlas of the human lung from single-cell RNA sequencing. Nature. 2020; 587(7835):619-625. PMC: 7704697. DOI: 10.1038/s41586-020-2922-4. View

Boucly A, Tu L, Guignabert C, Rhodes C, de Groote P, Prevot G . Cytokines as prognostic biomarkers in pulmonary arterial hypertension. Eur Respir J. 2022; 61(3). DOI: 10.1183/13993003.01232-2022. View

Merritt C, Ong G, Church S, Barker K, Danaher P, Geiss G . Multiplex digital spatial profiling of proteins and RNA in fixed tissue. Nat Biotechnol. 2020; 38(5):586-599. DOI: 10.1038/s41587-020-0472-9. View

Kheyfets V, Sweatt A, Gomberg-Maitland M, Ivy D, Condliffe R, Kiely D . Computational platform for doctor-artificial intelligence cooperation in pulmonary arterial hypertension prognostication: a pilot study. ERJ Open Res. 2023; 9(1). PMC: 9907150. DOI: 10.1183/23120541.00484-2022. View

Isobe S, Nair R, Kang H, Wang L, Moonen J, Shinohara T . Reduced FOXF1 links unrepaired DNA damage to pulmonary arterial hypertension. Nat Commun. 2023; 14(1):7578. PMC: 10663616. DOI: 10.1038/s41467-023-43039-y. View

Cunningham C, Li M, Ruffenach G, Doshi M, Aryan L, Hong J . Y-Chromosome Gene, , Protects Against Pulmonary Hypertension by Reducing Proinflammatory Chemokines. Am J Respir Crit Care Med. 2022; 206(2):186-196. PMC: 9887415. DOI: 10.1164/rccm.202110-2309OC. View

Alastalo T, Li M, De Jesus Perez V, Pham D, Sawada H, Wang J . Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. J Clin Invest. 2011; 121(9):3735-46. PMC: 3163943. DOI: 10.1172/JCI43382. View

Boucherat O, Yokokawa T, Krishna V, Kalyana-Sundaram S, Martineau S, Breuils-Bonnet S . Identification of LTBP-2 as a plasma biomarker for right ventricular dysfunction in human pulmonary arterial hypertension. Nat Cardiovasc Res. 2024; 1(8):748-760. DOI: 10.1038/s44161-022-00113-w. View

Ameen M, Sundaram L, Shen M, Banerjee A, Kundu S, Nair S . Integrative single-cell analysis of cardiogenesis identifies developmental trajectories and non-coding mutations in congenital heart disease. Cell. 2022; 185(26):4937-4953.e23. PMC: 10122433. DOI: 10.1016/j.cell.2022.11.028. View

10.

Alsafadi H, Staab-Weijnitz C, Lehmann M, Lindner M, Peschel B, Konigshoff M . An ex vivo model to induce early fibrosis-like changes in human precision-cut lung slices. Am J Physiol Lung Cell Mol Physiol. 2017; 312(6):L896-L902. DOI: 10.1152/ajplung.00084.2017. View

11.

Vo Q, Benam K . Advancements in preclinical human-relevant modeling of pulmonary vasculature on-chip. Eur J Pharm Sci. 2024; 195:106709. PMC: 10939731. DOI: 10.1016/j.ejps.2024.106709. View

12.

Tello K, Richter M, Yogeswaran A, Ghofrani H, Naeije R, Vanderpool R . Sex Differences in Right Ventricular-Pulmonary Arterial Coupling in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2020; 202(7):1042-1046. PMC: 7528786. DOI: 10.1164/rccm.202003-0807LE. View

13.

Omura J, Habbout K, Shimauchi T, Wu W, Breuils-Bonnet S, Tremblay E . Identification of Long Noncoding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension. Circulation. 2020; 142(15):1464-1484. DOI: 10.1161/CIRCULATIONAHA.120.047626. View

14.

Hu C, Zhang H, Laux A, Pullamsetti S, Stenmark K . Mechanisms contributing to persistently activated cell phenotypes in pulmonary hypertension. J Physiol. 2018; 597(4):1103-1119. PMC: 6375873. DOI: 10.1113/JP275857. View

15.

Van Der Feen D, Bossers G, Hagdorn Q, Moonen J, Kurakula K, Szulcek R . Cellular senescence impairs the reversibility of pulmonary arterial hypertension. Sci Transl Med. 2020; 12(554). PMC: 7891555. DOI: 10.1126/scitranslmed.aaw4974. View

16.

Humbert M, McLaughlin V, Gibbs J, Gomberg-Maitland M, Hoeper M, Preston I . Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension. Eur Respir J. 2022; 61(1). PMC: 9816418. DOI: 10.1183/13993003.01347-2022. View

17.

Aldred M, Morrell N, Guignabert C . New Mutations and Pathogenesis of Pulmonary Hypertension: Progress and Puzzles in Disease Pathogenesis. Circ Res. 2022; 130(9):1365-1381. PMC: 9897592. DOI: 10.1161/CIRCRESAHA.122.320084. View

18.

Gawad C, Koh W, Quake S . Single-cell genome sequencing: current state of the science. Nat Rev Genet. 2016; 17(3):175-88. DOI: 10.1038/nrg.2015.16. View

19.

Long L, Ormiston M, Yang X, Southwood M, Graf S, Machado R . Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nat Med. 2015; 21(7):777-85. PMC: 4496295. DOI: 10.1038/nm.3877. View

20.

Rachedi N, Tang Y, Tai Y, Zhao J, Chauvet C, Grynblat J . Dietary intake and glutamine-serine metabolism control pathologic vascular stiffness. Cell Metab. 2024; 36(6):1335-1350.e8. PMC: 11152997. DOI: 10.1016/j.cmet.2024.04.010. View